A phase II trial of interferon-α and 5-fluorouracil in patients with advanced renal cell carcinoma: A Southwest Oncology Group study

Medicine and Dentistry

• Interferon 100%
• Fluorouracil 100%
• Phase II Trials 100%
• Clear Cell Renal Cell Carcinoma 100%
• Inpatient 100%
• Oncology 100%
• Patient 50%
• Therapeutic Procedure 33%
• Diseases 16%
• Neoplasm 16%
• Overall Survival 16%
• Progression Free Survival 16%
• Toxicity 16%
• Drug Therapy 16%
• Combination Therapy 16%
• Intravenous Drug Administration 16%
• Malignant Neoplasm 16%
• Gastrointestinal Cancer 16%
• Kidney Metastasis 16%
• Chemotherapeutic Agent 16%
• Drug 16%
• Nephrectomy 16%
• Immunomodulating Agent 16%
• Recombinant Alpha2b Interferon 16%
• Cells 16%
• Clinical Trial 16%
• Cancer 16%

INIS

• patients 100%
• kidneys 100%
• interferon 100%
• carcinomas 100%
• uracils 100%
• cancer 33%
• drugs 16%
• clinical trials 16%
• therapy 16%
• diseases 16%
• performance 16%
• toxicity 16%
• refractories 16%
• infusion 16%
• metastases 16%
• malignancies 16%
• neoplasms 16%
• schedules 16%
• introns 16%
• nephrectomy 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Fluorouracil 100%
• Interferon 100%
• Renal Cell Carcinoma 100%
• Diseases 16%
• Overall Survival 16%
• Toxicity 16%
• Progression Free Survival 16%
• Neoplasm 16%
• Malignant Neoplasm 16%
• Recombinant Alpha2b Interferon 16%
• Kidney Metastasis 16%
• Immunomodulating Agent 16%
• Digestive System Cancer 16%
• Drug 16%